CORBIOPHARM: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
CORBIOPHARM
Largest movements
- Cash +€53,063
up €53,063 (+61.2%), from €86,638 to €139,701
mainly Trade debts (+€36,560) and Net result for the year (+€26,810)
- Stocks and contracts +€10,415
up €10,415 (+9.3%), from €112,063 to €122,478
- Tangible fixed assets -€6,170
down €6,170 (-22.6%), from €27,288 to €21,118
of which Land and buildings: -€3,212
- Receivables within one year +€3,311
up €3,311 (+9.3%), from €35,493 to €38,804
of which Trade receivables: +€5,794
- Trade debts +€36,560
up €36,560 (+35.3%), from €103,467 to €140,027
- Profit (loss) carried forward +€14,310
up €14,310, from -€13,909 to €401
- Other debts +€8,293
up €8,293 (+15.4%), from €53,922 to €62,215
- Staff costs -€24,245
down €24,245 (-29.7%), from €81,709 to €57,464
- Gross operating margin +€18,317
up €18,317 (+21.6%), from €84,982 to €103,299
- Taxes +€2,569
new in 2025: €2,569
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €261,482 | €322,101 | +€60,619 | +23.2% |
| Fixed assets | 21/28 | €27,288 | €21,118 | -€6,170 | -22.6% |
| Tangible fixed assets | 22/27 | €27,288 | €21,118 | -€6,170 | -22.6% |
| Land and buildings | 22 | €3,642 | €430 | -€3,212 | -88.2% |
| Plant, machinery and equipment | 23 | €8,596 | €7,122 | -€1,474 | -17.1% |
| Furniture and vehicles | 24 | €15,050 | €13,566 | -€1,484 | -9.9% |
| Current assets | 29/58 | €234,194 | €300,983 | +€66,789 | +28.5% |
| Stocks and contracts in progress | 3 | €112,063 | €122,478 | +€10,415 | +9.3% |
| Stocks | 30/36 | €112,063 | €122,478 | +€10,415 | +9.3% |
| Amounts receivable within one year | 40/41 | €35,493 | €38,804 | +€3,311 | +9.3% |
| Trade receivables | 40 | €29,350 | €35,144 | +€5,794 | +19.7% |
| Other amounts receivable | 41 | €6,143 | €3,660 | -€2,483 | -40.4% |
| Cash at bank and in hand | 54/58 | €86,638 | €139,701 | +€53,063 | +61.2% |
| Total equity and liabilities | 10/49 | €261,482 | €322,101 | +€60,619 | +23.2% |
| Equity | 10/15 | €92,472 | €106,782 | +€14,310 | +15.5% |
| Contributions | 10/11 | €62,000 | €62,000 | = | 0.0% |
| Capital | 10 | €62,000 | €62,000 | = | 0.0% |
| Issued capital | 100 | €62,000 | €62,000 | = | 0.0% |
| Reserves | 13 | €44,381 | €44,381 | = | 0.0% |
| Non-distributable reserves | 130/1 | €6,200 | €6,200 | = | 0.0% |
| Legal reserve | 130 | €6,200 | €6,200 | = | 0.0% |
| Distributable reserves | 133 | €38,181 | €38,181 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€13,909 | €401 | +€14,310 | |
| Amounts payable | 17/49 | €169,010 | €215,319 | +€46,309 | +27.4% |
| Amounts payable within one year | 42/48 | €168,867 | €214,757 | +€45,890 | +27.2% |
| Trade debts | 44 | €103,467 | €140,027 | +€36,560 | +35.3% |
| Suppliers | 440/4 | €103,467 | €140,027 | +€36,560 | +35.3% |
| Taxes, remuneration and social security | 45 | €11,478 | €12,515 | +€1,037 | +9.0% |
| Taxes | 450/3 | - | €2,569 | +€2,569 | |
| Remuneration and social security | 454/9 | €11,478 | €9,946 | -€1,532 | -13.3% |
| Other amounts payable | 47/48 | €53,922 | €62,215 | +€8,293 | +15.4% |
| Accrued charges and deferred income | 492/3 | €143 | €562 | +€419 | +293% |
| Remuneration, social security and pensions | 62 | €81,709 | €57,464 | -€24,245 | -29.7% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €13,289 | €13,670 | +€381 | +2.9% |
| Other operating charges | 640/8 | €472 | €710 | +€238 | +50.4% |
| Gross operating margin | 9900 | €84,982 | €103,299 | +€18,317 | +21.6% |
| Operating profit (loss) | 9901 | -€10,488 | €31,455 | +€41,943 | |
| Financial income | 75/76B | €268 | €650 | +€382 | +143% |
| Recurring financial income | 75 | €268 | €650 | +€382 | +143% |
| Financial charges | 65/66B | €3,689 | €2,726 | -€963 | -26.1% |
| Recurring financial charges | 65 | €3,689 | €2,726 | -€963 | -26.1% |
| Profit (loss) for the period before taxes | 9903 | -€13,909 | €29,379 | +€43,288 | |
| Income taxes | 67/77 | - | €2,569 | +€2,569 | |
| Profit (loss) for the period | 9904 | -€13,909 | €26,810 | +€40,719 | |
| Profit (loss) for the period to be appropriated | 9905 | -€13,909 | €26,810 | +€40,719 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 19 October 2026 via checked.be.